Kiniksa Pharmaceuticals Ltd
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
KNSA$98.76+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
| ITEM 11. | EXECUTIVE COMPENSATION. |
|---|
The information required to be disclosed by this Item will be set forth in our proxy statement for our 2024 Annual Meeting to be filed with the SEC within 120 days of December 31, 2023, and is incorporated into this Annual Report by reference.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.